Pyxis Oncology (NASDAQ:PYXS – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
Analyst Ratings
This is a breakdown of current ratings and price targets for Pyxis Oncology and Connect Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pyxis Oncology | 1 | 0 | 8 | 0 | 2.78 |
| Connect Biopharma | 1 | 0 | 8 | 0 | 2.78 |
Pyxis Oncology presently has a consensus price target of $8.71, suggesting a potential upside of 382.79%. Connect Biopharma has a consensus price target of $5.88, suggesting a potential upside of 895.76%. Given Connect Biopharma’s higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Pyxis Oncology.
Insider and Institutional Ownership
Profitability
This table compares Pyxis Oncology and Connect Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pyxis Oncology | N/A | -252.36% | -120.63% |
| Connect Biopharma | N/A | -220.02% | -145.03% |
Earnings and Valuation
This table compares Pyxis Oncology and Connect Biopharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pyxis Oncology | $13.86 million | 15.58 | -$79.62 million | ($1.30) | -1.39 |
| Connect Biopharma | $60,000.00 | 619.21 | -$55.48 million | ($1.14) | -0.52 |
Connect Biopharma has lower revenue, but higher earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Pyxis Oncology has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500.
Summary
Connect Biopharma beats Pyxis Oncology on 8 of the 11 factors compared between the two stocks.
About Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue. The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.
About Connect Biopharma
Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
